Syndax Pharmaceuticals
SNDX
115 hedge funds and large institutions have $862M invested in Syndax Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 54 increasing their positions, 31 reducing their positions, and 26 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 31
3.58% more ownership
Funds ownership: 100.5% → 104.08% (+3.6%)
12% less funds holding
Funds holding: 130 → 115 (-15)
20% less capital invested
Capital invested by funds: $1.08B → $862M (-$222M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
34% less call options, than puts
Call options by funds: $1.31M | Put options by funds: $1.99M
58% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$42.5M |
| 2 |
BlackRock
New York
|
+$15.4M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$14.1M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.6M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.5M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$24.1M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$22.9M |
| 4 |
VA
VR Adviser
New York
|
-$13.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.6M |
SNDX Hedge Fund Activity: Q2 2021 in Review
115 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2021, worth a combined $862M — down 20% from $1.08B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of SNDX and 11 opened new positions — a net loss of 15 holders — while 31 trimmed existing stakes and 54 added.
The largest buyer was BVF Inc, adding an estimated $42.5M. The largest seller was Wellington Management Group, cutting an estimated $24.5M.
- 115 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2021, down from 130 in Q1 2021.
- Funds reported $862M of Syndax Pharmaceuticals stock for Q2 2021, down 20% quarter-over-quarter.
- 11 funds opened new Syndax Pharmaceuticals positions in Q2 2021 and 26 closed out, a net change of -15 holders.
- The largest Syndax Pharmaceuticals buyer in Q2 2021 was BVF Inc, an estimated $42.5M added.
- The largest Syndax Pharmaceuticals seller in Q2 2021 was Wellington Management Group, an estimated $24.5M sold.
Based on aggregated 13F filings for Q2 2021.